Medical - Devices
Compare Stocks
2 / 10Stock Comparison
RCEL vs XTNT
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Devices
RCEL vs XTNT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Devices | Medical - Devices |
| Market Cap | $135M | $81M |
| Revenue (TTM) | $72M | $133M |
| Net Income (TTM) | $-49M | $2M |
| Gross Margin | 82.1% | 62.0% |
| Operating Margin | 89.0% | 4.8% |
| Total Debt | $2M | $35M |
| Cash & Equiv. | $10M | $6M |
RCEL vs XTNT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| AVITA Medical, Inc. (RCEL) | 100 | 13.7 | -86.3% |
| Xtant Medical Holdi… (XTNT) | 100 | 46.9 | -53.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: RCEL vs XTNT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
RCEL is the clearest fit if your priority is long-term compounding.
- -57.1% 10Y total return vs XTNT's -97.6%
XTNT carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.69
- Rev growth 28.4%, EPS growth 107.7%, 3Y rev CAGR 28.5%
- Lower volatility, beta 0.69, Low D/E 81.8%, current ratio 2.35x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 28.4% revenue growth vs RCEL's 11.5% | |
| Quality / Margins | 1.3% margin vs RCEL's -67.8% | |
| Stability / Safety | Beta 0.69 vs RCEL's 1.83 | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +13.5% vs RCEL's -52.0% | |
| Efficiency (ROA) | 1.8% ROA vs RCEL's -86.2%, ROIC -12.8% vs 8.2% |
RCEL vs XTNT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
RCEL vs XTNT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
XTNT leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
XTNT is the larger business by revenue, generating $133M annually — 1.9x RCEL's $72M. XTNT is the more profitable business, keeping 1.3% of every revenue dollar as net income compared to RCEL's -67.8%. On growth, XTNT holds the edge at +19.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $72M | $133M |
| EBITDAEarnings before interest/tax | $64M | $11M |
| Net IncomeAfter-tax profit | -$49M | $2M |
| Free Cash FlowCash after capex | -$31M | $5M |
| Gross MarginGross profit ÷ Revenue | +82.1% | +62.0% |
| Operating MarginEBIT ÷ Revenue | +89.0% | +4.8% |
| Net MarginNet income ÷ Revenue | -67.8% | +1.3% |
| FCF MarginFCF ÷ Revenue | -43.6% | +3.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | -4.3% | +19.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +15.9% | +123.7% |
Valuation Metrics
XTNT leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $135M | $81M |
| Enterprise ValueMkt cap + debt − cash | $127M | $110M |
| Trailing P/EPrice ÷ TTM EPS | -2.54x | -4.81x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 1.99x | — |
| Price / SalesMarket cap ÷ Revenue | 1.89x | 0.69x |
| Price / BookPrice ÷ Book value/share | — | 1.80x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
RCEL leads this category, winning 5 of 6 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), RCEL scores 3/9 vs XTNT's 2/9, reflecting mixed financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | — | +3.8% |
| ROA (TTM)Return on assets | -86.2% | +1.8% |
| ROICReturn on invested capital | +8.2% | -12.8% |
| ROCEReturn on capital employed | +2.4% | -17.9% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 2 |
| Debt / EquityFinancial leverage | — | 0.82x |
| Net DebtTotal debt minus cash | -$8M | $29M |
| Cash & Equiv.Liquid assets | $10M | $6M |
| Total DebtShort + long-term debt | $2M | $35M |
| Interest CoverageEBIT ÷ Interest expense | — | 1.55x |
Total Returns (Dividends Reinvested)
XTNT leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in XTNT five years ago would be worth $3,395 today (with dividends reinvested), compared to $2,284 for RCEL. Over the past 12 months, XTNT leads with a +13.5% total return vs RCEL's -52.0%. The 3-year compound annual growth rate (CAGR) favors XTNT at -3.9% vs RCEL's -34.9% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +27.4% | -23.1% |
| 1-Year ReturnPast 12 months | -52.0% | +13.5% |
| 3-Year ReturnCumulative with dividends | -72.4% | -11.2% |
| 5-Year ReturnCumulative with dividends | -77.2% | -66.1% |
| 10-Year ReturnCumulative with dividends | -57.1% | -97.6% |
| CAGR (3Y)Annualised 3-year return | -34.9% | -3.9% |
Risk & Volatility
XTNT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
XTNT is the less volatile stock with a 0.69 beta — it tends to amplify market swings less than RCEL's 1.83 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. XTNT currently trades 60.7% from its 52-week high vs RCEL's 44.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.83x | 0.69x |
| 52-Week HighHighest price in past year | $9.85 | $0.95 |
| 52-Week LowLowest price in past year | $3.22 | $0.44 |
| % of 52W HighCurrent price vs 52-week peak | +44.9% | +60.7% |
| RSI (14)Momentum oscillator 0–100 | 45.2 | 61.8 |
| Avg Volume (50D)Average daily shares traded | 205K | 143K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — |
| Price TargetConsensus 12-month target | $6.75 | — |
| # AnalystsCovering analysts | 7 | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
XTNT leads in 4 of 6 categories (Income & Cash Flow, Valuation Metrics). RCEL leads in 1 (Profitability & Efficiency).
RCEL vs XTNT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is RCEL or XTNT a better buy right now?
For growth investors, Xtant Medical Holdings, Inc.
(XTNT) is the stronger pick with 28. 4% revenue growth year-over-year, versus 11. 5% for AVITA Medical, Inc. (RCEL). Analysts rate AVITA Medical, Inc. (RCEL) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — RCEL or XTNT?
Over the past 5 years, Xtant Medical Holdings, Inc.
(XTNT) delivered a total return of -66. 1%, compared to -77. 2% for AVITA Medical, Inc. (RCEL). Over 10 years, the gap is even starker: RCEL returned -57. 1% versus XTNT's -97. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — RCEL or XTNT?
By beta (market sensitivity over 5 years), Xtant Medical Holdings, Inc.
(XTNT) is the lower-risk stock at 0. 69β versus AVITA Medical, Inc. 's 1. 83β — meaning RCEL is approximately 165% more volatile than XTNT relative to the S&P 500.
04Which is growing faster — RCEL or XTNT?
By revenue growth (latest reported year), Xtant Medical Holdings, Inc.
(XTNT) is pulling ahead at 28. 4% versus 11. 5% for AVITA Medical, Inc. (RCEL). Over a 3-year CAGR, XTNT leads at 28. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — RCEL or XTNT?
Xtant Medical Holdings, Inc.
(XTNT) is the more profitable company, earning -14. 0% net margin versus -67. 8% for AVITA Medical, Inc. — meaning it keeps -14. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RCEL leads at 89. 0% versus -10. 3% for XTNT. At the gross margin level — before operating expenses — RCEL leads at 82. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — RCEL or XTNT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is RCEL or XTNT better for a retirement portfolio?
For long-horizon retirement investors, Xtant Medical Holdings, Inc.
(XTNT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 69)). AVITA Medical, Inc. (RCEL) carries a higher beta of 1. 83 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (XTNT: -97. 6%, RCEL: -57. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between RCEL and XTNT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: RCEL is a small-cap quality compounder stock; XTNT is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.